GDF-8: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข4 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Biologic myostatin inhibitors should be stored at 2-8 degrees C (refrigerated). Do not freeze unless product labeling specifically permits it. Protect from light. Reconstituted solutions should be used within the timeframe specified in product documentation.
Protocol Quick-Reference
Muscle growth via myostatin pathway inhibition (investigational; multiple agents in clinical trials)
Dosing
Amount
Agent-dependent: MYO-029 10-30 mg/kg IV single dose; Domagrozumab 20-40 mg/kg IV q4w; Bimagrumab 70 mg SC q4w or 10 mg/kg IV q4w
Frequency
Every 2-4 weeks depending on agent
Duration
24-48 weeks in clinical trials
Administration
Route
IVSchedule
Every 2-4 weeks depending on agent
Timing
No specific time of day; administered in clinical settings for IV agents
Cycle
Duration
24-48 weeks in clinical trials
Repeatable
Yes
Preparation & Storage
Storage: Biologic myostatin inhibitors should be stored at 2-8 degrees C (refrigerated). Do not freeze unless product labeling specifically permits it. Protect from light. Reconstituted solutions should be used within the timeframe specified in product documentation.
โ๏ธ Suggested Bloodwork (6 tests)
DEXA scan
When: Baseline
Why: Baseline lean and fat mass measurement
Muscle MRI (if available)
When: Baseline
Why: Baseline muscle volume assessment
CBC with differential
When: Baseline
Why: Baseline blood counts
CMP
When: Baseline
Why: Liver and kidney function
CK (creatine kinase)
When: Baseline
Why: Baseline muscle enzyme
Echocardiogram
When: Baseline
Why: Baseline cardiac function; theoretical concern for cardiac hypertrophy
๐ก Key Considerations
- โContraindication: Avoid in patients with cardiac disorders (theoretical hypertrophy risk); ACE-031-type agents contraindicated in patients with bleeding disorders due to BMP9/10 inhibition
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Anti-myostatin antibody (MYO-029) Phase I/II | 1, 3, 10, or 30 mg/kg | Single IV infusion | Single dose with 6-month follow-up | Dose-escalation safety study in adult muscular dystrophy patients |
| Domagrozumab (PF-06252616) Phase 2 DMD | 5 mg/kg (low), 20 mg/kg (mid), 40 mg/kg (high) | Every 4 weeks IV | 48 weeks treatment period | Phase 2 trial in ambulatory DMD patients |
| ACE-031 Phase 1 healthy volunteers | 0.02 to 3 mg/kg | Single SC injection | Single dose with follow-up | Dose-escalation study; higher doses showed lean mass increases |
| Bimagrumab Phase 2 sarcopenia | 70 mg SC every 4 weeks | Every 4 weeks | 24-48 weeks | Lower doses than IV formulation due to different pharmacokinetics |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
Myostatin inhibitor biologics are supplied as sterile solutions for injection or as lyophilized powder requiring reconstitution with sterile water for injection per manufacturer protocol. Specific preparation varies by product.
Recommended Injection Sites
- โIntravenous infusion (monoclonal antibodies)
- โSubcutaneous (some antibodies, ActRIIB-Fc)
- โIntramuscular (gene therapy approaches)
๐งStorage Requirements
Biologic myostatin inhibitors should be stored at 2-8 degrees C (refrigerated). Do not freeze unless product labeling specifically permits it. Protect from light. Reconstituted solutions should be used within the timeframe specified in product documentation.
Community Dosing Protocols
Compare these clinical doses with what 20+ community members report using.
Based on 20+ community reports
View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Research Dosing Disclaimer#
No myostatin inhibitor has received regulatory approval for therapeutic use. All dosing information is derived from clinical trials and is provided for educational reference only. Myostatin-targeted therapies are investigational and available only through clinical trials.
Clinical Trial Dosing#
Stamulumab (MYO-029) โ First Anti-Myostatin Antibody#
The Phase I/II trial of stamulumab used a dose-escalation design in patients with Becker muscular dystrophy, facioscapulohumeral dystrophy, or limb-girdle muscular dystrophy:
- Cohort 1: 1 mg/kg single IV infusion
- Cohort 2: 3 mg/kg single IV infusion
- Cohort 3: 10 mg/kg single IV infusion
- Cohort 4: 30 mg/kg single IV infusion
Patients were followed for approximately 6 months after the single infusion. Dose-dependent trends in lean body mass were observed at the higher doses (10 and 30 mg/kg), but functional outcomes did not improve significantly. The antibody exhibited linear pharmacokinetics with a half-life of approximately 2 weeks.
Domagrozumab (PF-06252616) โ Duchenne Muscular Dystrophy#
The Phase 2 HALO trial evaluated three dose levels administered every 4 weeks by intravenous infusion:
- Low dose: 5 mg/kg every 4 weeks
- Mid dose: 20 mg/kg every 4 weeks
- High dose: 40 mg/kg every 4 weeks
Treatment continued for 48 weeks. The primary endpoint was change in 4-stair climb velocity. Despite biological activity (increases in thigh muscle volume by MRI), the primary functional endpoint was not met at any dose level.
ACE-031 โ Soluble ActRIIB-Fc#
ACE-031 was studied in a dose-escalation Phase 1 trial in healthy postmenopausal women:
- Doses ranged from 0.02 to 3 mg/kg administered as a single subcutaneous injection
- At 1 mg/kg and above, significant increases in lean body mass were observed (approximately 1 kg at 29 days)
- The half-life was approximately 10-15 days, supporting monthly dosing
- Higher doses were associated with epistaxis and telangiectasia
The subsequent trial in DMD patients was halted before completion due to vascular safety signals.
Bimagrumab (BYM338) โ Anti-ActRIIA#
Bimagrumab has been studied in multiple indications:
- Sarcopenia: 70 mg SC every 4 weeks for 24-48 weeks
- Sporadic inclusion body myositis: 10 mg/kg IV every 4 weeks
- Obesity: 10 mg/kg IV every 4 weeks for 48 weeks
The drug showed consistent increases in lean body mass across indications, with the largest effects seen in obesity trials where significant fat mass reduction was also observed.
Administration Considerations#
Route of Administration#
The route of administration varies by product class:
| Agent Type | Route | Frequency | Rationale |
|---|---|---|---|
| Anti-myostatin antibody | IV or SC | Every 2-4 weeks | Standard biologic antibody PK |
| ActRIIB-Fc fusion | SC | Every 2-4 weeks | Receptor fusion protein PK |
| Follistatin gene therapy | Intramuscular | Single | Permanent gene expression |
| Myostatin propeptide | IV or SC | Frequent | Short half-life |
Pharmacokinetic Considerations#
Monoclonal antibodies targeting myostatin exhibit typical IgG pharmacokinetics:
- Half-life of approximately 2-3 weeks
- Linear pharmacokinetics across the dose ranges studied
- Steady-state achieved after 3-4 doses with every-4-week dosing
- Anti-drug antibodies may develop and affect exposure
Dose-Response Relationship#
A consistent finding across myostatin inhibitor trials is that biological activity (increased lean body mass) is dose-dependent and demonstrable, but functional improvement has been much harder to achieve. This dose-response dissociation โ where higher doses produce more muscle mass but not proportionally more function โ has been a central challenge in the field and has implications for optimal dose selection.
Monitoring Requirements#
Patients in myostatin inhibitor trials are typically monitored for:
- Body composition: DEXA scanning for lean and fat mass changes
- Muscle volume: MRI of target muscles
- Functional tests: 6-minute walk test, timed stair climb, grip strength
- Cardiac function: Echocardiography for potential cardiac hypertrophy
- Laboratory markers: CK, liver function, renal function, reproductive hormones
- Immunogenicity: Anti-drug antibody development
- Vascular safety: For broader-spectrum inhibitors (BMP9/10 effects)
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About GDF-8
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.